The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | An analysis of transfusion-related cost offsets & time burden in pts with MF in the MOMENTUM trial
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the findings of a post-hoc analysis that investigated the transfusion-related cost offsets and time burden in patients with myelofibrosis (MF) and anemia treated with momelotinib versus danazol in the MOMENTUM trial (NCT04173494). Treatment with momelotinib resulted in the need for fewer transfusions, ultimately leading to reduced financial burden and time toxicity in patients with the disease. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support/advisory board participation: Cogent, GSK, Morphosys, PharmaEssentia.
